Life Sciences Commercialisation in Finland: Overview - Dittmar & Indrenius

Transaction Powerhouse

Probably the most reputable legal partner in Finland.

IFLR1000, Financial and corporate

Dittmar & Indrenius
Attorneys Ltd.
Pohjoisesplanadi 25 A
FI-00100 Helsinki, Finland
+358 9 681 700
office@dittmar.fi
Business ID: 0217099-4
VAT number: FI02170994

Service areas

Written by

Charlotta Bonsdorff

Senior Associate

Juli Mansnérus

Partner

juli.mansnerus@dittmar.fi +358 44 272 4727

Inari Paila

Senior Attorney

inari.paila@dittmar.fi +358 50 388 9591

Emilia Rosenblad

Associate

emilia.rosenblad@dittmar.fi +358 40 082 6562

A Q&A guide to life sciences commercialisation in Finland.

This Q&A provides a high-level overview of key practical issues, including the life sciences sector, pricing and state funding, distribution and sale, importing, advertising, patents, trade marks, competition law, and product liability.

Read the Finland chapter we contributed: Life Sciences Commercialisation in Finland: Overview

Read also: Life Sciences Regulation in Finland: Overview

Written by

Charlotta Bonsdorff

Senior Associate

Juli Mansnérus

Partner

juli.mansnerus@dittmar.fi +358 44 272 4727

Inari Paila

Senior Attorney

inari.paila@dittmar.fi +358 50 388 9591

Emilia Rosenblad

Associate

emilia.rosenblad@dittmar.fi +358 40 082 6562

Service areas

More by the same author

Reform of the Act on the Secondary Use of Social and Health Data

The Act on the Secondary Use of Social and Health Data (552/2019) is being reformed The Act on the Secondary Use of Social and Health Data (552/2019) (the “Secondary Use Act”), which lays out rules on the use of social and health data in Finland for secondary purposes, entered into force in May 2019. Secondary use of social and health data refers to the use of such data for statistics, scientific research, development and innovation, education, policy-making and regulatory activities by public authorities.

New Legislation on Environmental Marketing: Sustainable Businesses Benefit from Ban on Greenwashing

New EU legislation on green claims will bring opportunities to sustainable businesses, although ensuring compliance with the new rules will require preparatory efforts from companies. As stricter and more detailed rules will apply to environmental claims and marketing, to prevent so-called greenwashing, companies with a genuinely sustainable product range will benefit from the new framework. Prohibition of greenwashing brings advantages to both consumers and businesses – and naturally to the environment.

The EU’s Pharmaceutical Legislation Reform

The European Union’s imminent pharmaceutical legislation reform aims to modernise its regulatory framework, focusing on improving patient access to medicines, fostering innovation, and minimising environmental impact. This strategic overhaul, set against a backdrop of industry challenges and evolving IP rights, underscores the EU’s commitment to balancing innovation with accessibility and sustainability in healthcare.

Latest insights

The Clean Industrial Deal: Strategic Incentives to Decarbonise Industry

Alert / 28 Feb 2025

DORA Is Now Applicable - Key Implications for ICT Service Providers

Alert / 20 Jan 2025

Reading time 4 minutes